0000000000766208

AUTHOR

Heiner K. Berthold

showing 4 related works from this author

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Mipomersen: a lipid-lowering agent with a novel mechanism of action

2013

“...mipomersen is a ... valuable alternative to apheresis for patients with heterozygous familial hypercholesterolemia.”

inorganic chemicalsLdl cholesterolChemistryEndocrinology Diabetes and MetabolismMipomersenLipid-lowering agentnutritional and metabolic diseasesPharmacologybehavioral disciplines and activitieshumanitiesantisense oligonucleotides LDL cholesterol lipid lowering mipomersen statinsApheresisMechanism of actionAntisense oligonucleotidesmedicineLipid loweringmedicine.symptomCardiology and Cardiovascular Medicinehealth care economics and organizationsClinical Lipidology
researchProduct

Heat Shock Protein-60 and Risk for Cardiovascular Disease

2011

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecularchaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60,the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotectivebut a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examplesof specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicatea pathogenic role for HSP60 but also its …

Riskanimal structuresChaperonin Heat shock protein-60 cardiomyocytes heart failure cardiovascular diseases atherosclerosisChaperonin heat shock protein 60 cardiomyocytes heart failure cardiovascular disease atherosclerosis apoptosis microRNAs (miRs) diabetes Atrial fibrillationApoptosischemical and pharmacologic phenomenaDiseaseBioinformaticsAutoimmune DiseasesPathogenesisHeat shock proteinAtrial FibrillationDrug DiscoveryExtracellularAnimalsHumansMyocytes CardiacHeart FailurePharmacologybiologyfungiChaperonin 60AtherosclerosisResponse to treatmentCardiovascular DiseasesReperfusion InjuryChaperone (protein)HypertensionImmunologybiology.proteinHSP60Stress conditionsBiomarkersCurrent Pharmaceutical Design
researchProduct